Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.580
-0.030 (-1.86%)
At close: Oct 7, 2025, 4:00 PM EDT
1.571
-0.009 (-0.59%)
After-hours: Oct 7, 2025, 7:19 PM EDT

Galmed Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
3.533.33.924.665.664.13
Upgrade
Research & Development
3.52.983.571327.2226.08
Upgrade
Operating Expenses
7.036.287.4917.6532.8830.21
Upgrade
Operating Income
-7.03-6.28-7.49-17.65-32.88-30.21
Upgrade
Interest Expense
-0.61-0.61----
Upgrade
Interest & Investment Income
0.550.50.380.30.561.19
Upgrade
Currency Exchange Gain (Loss)
0.040.04-0.040.04-0.03-0.12
Upgrade
Other Non Operating Income (Expenses)
-0.02-0.020.25-0.02-0.04-0.03
Upgrade
EBT Excluding Unusual Items
-7.07-6.36-6.9-17.34-32.39-29.17
Upgrade
Gain (Loss) on Sale of Investments
-1.66-1.16-0.01-0.53-0.080.4
Upgrade
Pretax Income
-8.72-7.52-6.91-17.87-32.47-28.77
Upgrade
Net Income
-8.72-7.52-6.91-17.87-32.47-28.77
Upgrade
Net Income to Common
-8.72-7.52-6.91-17.87-32.47-28.77
Upgrade
Shares Outstanding (Basic)
210000
Upgrade
Shares Outstanding (Diluted)
210000
Upgrade
Shares Change (YoY)
323.44%303.31%65.23%2.22%15.59%0.79%
Upgrade
EPS (Basic)
-4.27-8.08-29.95-127.90-237.59-243.35
Upgrade
EPS (Diluted)
-4.27-8.08-29.95-127.90-237.59-243.35
Upgrade
Free Cash Flow
-5.47-5.88-6.14-18.51-32.9-26.33
Upgrade
Free Cash Flow Per Share
-2.68-6.32-26.59-132.48-240.78-222.72
Upgrade
EBITDA
-6.99-6.2-7.46-17.62-32.84-30.17
Upgrade
D&A For EBITDA
0.040.080.030.040.040.04
Upgrade
EBIT
-7.03-6.28-7.49-17.65-32.88-30.21
Upgrade
Updated Aug 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q